gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ANABHealthcarePharmaceuticals

AnaptysBio, Inc. Common Stock (ANAB)

$47.35−0.80%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$47.73▲ 32.44% in range
Nov 3, 2025Low $33.09 · High $70.22Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

AnaptysBio closed at $47.35 on Nov 4, down 0.80%, 32.6% below its 52-week closing high. Volume of 207.8K shares was 0.44× its 20-day average (below normal).

Split-adjusted performance: -1.1% over one month, -29.7% over six months, +31.4% over one year.

In the quarter ended Mar 31, 2026, revenue was $25.56M, down 8.0% from a year earlier, with a net margin of -206.9%.

Short interest was 5.4M shares at the Oct 15 settlement, up 3.0% from the prior report (30.6% of float, 10.6 days to cover).

Market cap$1.42B29.9M shares
Revenue · quarter$25.6M−8.0% YoY
Diluted EPS$-1.84—
P/E · TTM—P/S 6.1×
Net margin-206.9%Gross 100.0%
Dividend yieldNone
52-week range33.09 – 70.22−32.6% from high
Volume207.8K0.44× 20-day avg
Volatility · 60d40.0%Annualised
Short % of float30.6%10.6 days to cover
Net cash$286.5MCash $286.5M
Next earnings—Not scheduled
Split-adjusted performance
1W −6.2%1M −1.1%3M −13.5%6M −29.7%YTD −2.3%1Y +31.4%3Y +187.1%5Y +52.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum45
Revenue growth35
Net margin38
Value (low P/E)—
Size75

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short5.4M+3.0% vs prior
Days to cover10.6Settled Oct 15
% of float30.6%
Short vol. 10d47.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ANABAnaptysBio$47.35−0.80%−29.7%−8.0%−206.9%—$1.42B
KARDKardigan$14.99+4.68%————$1.40BCompare
KRSAKorsana Biosciences$30.55−4.43%————$1.39BCompare
DMRADamora Therapeutics$22.42+1.54%————$1.38BCompare
PCRXPacira BioSciences$36.43+0.10%+53.8%+6.2%2.4%99.3$1.45BCompare
URGNUroGen Pharma$29.81−13.34%+13.6%+199.2%−19.8%—$1.46BCompare
RAPPRapport Therapeutics$25.93+1.93%−30.0%———$1.46BCompare
TYRATyra Biosciences$21.31−0.30%−37.0%———$1.46BCompare
MLYSMineralys Therapeutics$16.67+4.22%−44.7%———$1.47BCompare

News about AnaptysBio

All news →
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research · Oct 27, 2026▲ PositiveAnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research · Sep 21, 2026▼ Negative

Quick answers

What does AnaptysBio do?
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology.
What is ANAB's market cap?
$1.42B, based on the Nov 4 close of $47.35.
Does AnaptysBio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ANAB is sold short?
5.4M shares, 30.6% of float, as of Oct 15, 2026.
What sector is ANAB in?
Healthcare, in the Pharmaceuticals industry.

About AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

HQ: San Diego, CA104 employeesListed Jan 26, 2017anaptysbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology